Chemoprevention of breast cancer (Q57133081)

Europe PubMed Central

title

Chemoprevention of breast cancer (English)

0 references

author name string

Julia A Files

1

0 references

Daniela L Stan

2

0 references

Summer V Allen

3

0 references

Sandhya Pruthi

Estrogen carcinogenesis in breast cancer

4

0 references

language of work or name

English

0 references

publication date

November 2012

0 references

published in

Women's Health

0 references

volume

8

0 references

page(s)

635-46

0 references

issue

6

0 references

cites work

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

The decrease in breast-cancer incidence in 2003 in the United States

21 January 2018

1 reference

Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible

21 January 2018

1 reference

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.

21 January 2018

1 reference

A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis

21 January 2018

1 reference

Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis

21 January 2018

1 reference

Assessment of the accuracy of the Gail model in women with atypical hyperplasia

21 January 2018

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

Clinical effects of raloxifene hydrochloride in women

21 January 2018

1 reference

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

21 January 2018

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

Aromatase inhibitors for breast cancer prevention

21 January 2018

1 reference

Exemestane for breast-cancer prevention in postmenopausal women.

21 January 2018

1 reference

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial

21 January 2018

1 reference

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer

21 January 2018

1 reference

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

Managing aromatase inhibitors in breast cancer survivors: not just for oncologists

21 January 2018

1 reference

The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention

21 January 2018

1 reference

Breast cancer chemoprevention

21 January 2018

1 reference

Progress in endocrine approaches to the treatment and prevention of breast cancer

21 January 2018

1 reference

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

21 January 2018

1 reference

Patient reluctance toward tamoxifen use for breast cancer primary prevention

21 January 2018

1 reference

The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer.

21 January 2018

1 reference

Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis

21 January 2018

1 reference

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors

21 January 2018

1 reference

Explanations for side effect aversion in preventive medical treatment decisions

21 January 2018

1 reference

Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point

21 January 2018

1 reference

Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention

21 January 2018

1 reference

Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial

21 January 2018

1 reference

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

21 January 2018

1 reference

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older

21 January 2018

1 reference

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

21 January 2018

1 reference

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

21 January 2018

1 reference

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

21 January 2018

1 reference

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

21 January 2018

1 reference

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

21 January 2018

1 reference

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force

21 January 2018

1 reference

The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women

21 January 2018

1 reference

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

21 January 2018

1 reference

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

21 January 2018

1 reference

Metformin in cancer: translational challenges

21 January 2018

1 reference

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference